Ultragenyx Announces 24-week Data From First Cohort Of Phase 1/2 Study Of DTX401 Gene Therapy In Glycogen Storage Disease Type Ia; Response In Time To Hypoglycemia And Improved Glucose Control Maintained Or Improved In All Three Patients
Benzinga Newsdesk